Trump signs memorandum to restrict investments that do not serve American interests; A Jiangsu court ruled that investments ...

Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications ...

State Council defines concentrations of business operators of the pharmaceutical sector. Network trading platform operators are required to submit information on the identities of online trading ...

China’s intellectual property law space. [Danlei Wu] of [Fangda Partners] examines the key developments and the indicators for further developments in the year ahead ...

Philip Qu of TransAsia Lawyers analyze regulatory and statutory progress in China’s ever flourishing TMT sector in 2024, and look at the outlook for 2025 ...

Casper Sek of Jingtian & Gongcheng examines the evolution and refinement of China’s data protection oversight throughout 2024 ...

Casper Sek and Alan Zhang of Jingtian & Gongcheng provide answers to key questions on China’s data transfer regime, and identify some vital trends “There are typically no specific restrictions on the ...

Simon Leung, Partner of Baker McKenzie, and Terry Xu, Senior Counsel at FenXun Partners, examine key regulatory shifts in 2024 and provide an outlook of potential regulatory trends for the banking and ...